Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$25.24 USD

25.24
18,327,111

-0.21 (-0.83%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $25.29 +0.05 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks News

Sweta Killa headshot

JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm

The U.S. regulators recommended an immediate pause on the use of Johnson & Johnson's (JNJ) COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.

Zacks Equity Research

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

Zacks Equity Research

Stock Market News for Apr 14, 2021

The S&P 500 and the Nasdaq closed in the green on Tuesday backed by solid gains in tech stocks.

Kinjel Shah headshot

Which Vaccine Maker Will Win the Fight Against COVID-19?

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Zacks Equity Research

J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation

FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.

Mark Vickery headshot

S&P 500 Hits Another New All-Time High

The index's totals weren't super-noteworthy in the daily performance, +0.33%, but this April has seen multiple new highs four of the past six sessions.

Zacks Equity Research

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

Zacks Equity Research

Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Zacks Equity Research

Consumer Price Index Rise 0.6%

Consumer Price Index Rise 0.6%

Mark Vickery headshot

CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?

Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study

Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.

Zacks Equity Research

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Stock Market News for Apr 12, 2021

Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism

Zacks Equity Research

J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots

The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

Zacks Equity Research

ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data

ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.

Zacks Equity Research

Higher-Than-Expected PPI in March

Higher-Than-Expected PPI in March.

Zacks Equity Research

Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study

Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.

Mark Vickery headshot

PPI Doubles Month Over Month to 1.0%

We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.

Zacks Equity Research

Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study

Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

Zacks Equity Research

Earnings Estimates Rising for Moderna (MRNA): Will It Gain?

Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study

Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.

Zacks Equity Research

Company News for Apr 7, 2021

Companies in The News Are: ILMN, NVAX, MRNA, BP.